Frequency of atazanavir-associated leukocyturia development and renal function decline

Dbeibo, Lana; Arif, Sana; He, Fang; Gupta, Samir K.

doi:10.1097/qad.0000000000001061

Cited by 1 publication

(1 citation statement)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Five patients with leukocyturia at baseline had less than 5 WBCs at last assessment. There was no significant decrease in eGFR (−0.3187 mL/min/1.73 m 2 , p =0.689) [ 65 ]. Patients with stable HIV disease (n=49, undetectable viral load and CD4 >200 cells/mm 3 ) who were receiving either ATV or ATV/r had ATV plasma levels obtained to assess any association with ATV and renal function.…”

Section: Protease Inhibitors (Pis)mentioning

confidence: 99%

Renal effects of non-tenofovir antiretroviral therapy in patients living with HIV

McLaughlin¹,

Guerrero²,

Merker³

2018

DIC

View full text Add to dashboard Cite

A review of literature published regarding non-tenofovir antiretroviral agents causing renal adverse effects was conducted. The literature involving renal adverse effects and antiretroviral therapy is most robust with protease inhibitors, specifically atazanavir and indinavir, and includes reports of crystalluria, leukocyturia, nephritis, nephrolithiasis, nephropathy and urolithiasis. Several case reports describe potential nephropathy (including Fanconi syndrome) secondary to administration of abacavir, didanosine, lamivudine and stavudine. Case reports documented renal events such as acute renal failure, nephritis, proteinuria and renal stones with efavirenz administration. Regarding rilpivirine, a small increase of serum creatinine levels (SCr) was found in clinical trials; however, the clinical significance and impact on actual renal function is unknown. The integrase strand transfer inhibitors and enfuvirtide have a relatively safe renal profile, although studies have shown dolutegravir and raltegravir cause mild elevations in SCr without an impact on actual renal function. This is similar to the reaction observed with cobicistat, the pharmacokinetic enhancer frequently given with elvitegravir.

show abstract

Section: Protease Inhibitors (Pis)mentioning

confidence: 99%